记能达^® （多奈单抗注射液）

多奈单抗用于阿尔茨海默病的1b期研究：通过Florbetapir F18成像测量的脑淀粉样蛋白的快速和持续减少

Donanemab (LY3002813) Phase 1b study in Alzheimer's disease: Rapid and sustained reduction of amyloid measured by Florbetapir F18 imaging

发表日期：2021-09-21

多奈单抗在阿尔茨海默病中的剂量递增研究

Donanemab (LY3002813) dose-escalation study in Alzheimer's Disease

发表日期：2021-02-14

使用建模方法研究阿尔茨海默病中多奈单抗的暴露与疗效关系

Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease

发表日期：2023-06-28

APOE ε4对早期症状性阿尔茨海默病中淀粉样蛋白治疗反应的影响：来自多个临床试验的分析

APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials

发表日期：2023-05-19

“节省时间”作为临床意义的展示，并使用多奈单抗 TRAILBLAZER-ALZ研究结果进行说明

'Time Saved' As A Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings

发表日期：2023-05-03

多奈单抗在人群药代动力学、淀粉样斑块减少和阿尔茨海默病受试者中的安全性

Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer's disease

发表日期：2023-02-18

通过iADRS测量的阿尔茨海默病中的有意义临床变化，并使用多奈单抗 TRAILBLAZER-ALZ研究结果进行说明

Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings

发表日期：2023-02-16

使用综合阿尔茨海默病评分量表的疾病进展模型

Disease progression model using the integrated Alzheimer's Disease Rating Scale

发表日期：2022-11-30

在早期症状性阿尔茨海默病中多奈单抗的治疗与探索性血浆生物标志物的关联：TRAILBLAZER-ALZ随机临床试验的二次分析

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial

发表日期：2022-10-17

多奈单抗治疗后淀粉样蛋白减少与Tau病理和临床结局的关联：TRAILBLAZER-ALZ随机临床试验

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.

发表日期：2022-09-12

多奈单抗在早期阿尔茨海默病中的应用

Donanemab in early Alzheimer's disease

发表日期：2021-03-13

减缓早期症状性阿尔茨海默病进展对患者生活质量、照护时间和社会总成本的潜在影响：基于GERAS-US研究结果的估计

Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer's Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study

发表日期：2024-06-08

多奈单抗在早期阿尔茨海默病日本患者中的应用：TRAILBLAZER-ALZ 2随机试验的亚群分析

Donanemab in Japanese Patients with Early Alzheimer’s Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial

发表日期：2024-04-06

多奈单抗数据如何解决证据开发问题的覆盖

How donanemab data address the coverage with evidence development questions.

发表日期：2024-02-07

在临床试验中使用Tau作为诊断工具来预测阿尔茨海默病中的淀粉样蛋白

Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease

发表日期：2023-08-16

多奈单抗在早期症状性阿尔茨海默病中的应用：TRAILBLAZER-ALZ 2随机临床试验

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

发表日期：2023-07-17

GERAS-US研究三年随访中的疾病进展和成本

Disease progression and costs at the 3-year follow-up of the GERAS-US study

发表日期：2023-05-19

根据严重程度和淀粉样蛋白-β状态对早期阶段痴呆进行临床和经济评估：对GERAS-US患者的五年回顾性索赔研究

Clinical and Economic Assessment in Early-Stage Dementia by Severity and Amyloid-β Status: A 5-Year Retrospective Claims Study of GERAS-US Patients

发表日期：2022-12-05

综合阿尔茨海默病评分量表：临床意义变化的评估

Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates

发表日期：2022-06-06